<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01655511</url>
  </required_header>
  <id_info>
    <org_study_id>B3461040</org_study_id>
    <secondary_id>B3461040</secondary_id>
    <nct_id>NCT01655511</nct_id>
  </id_info>
  <brief_title>Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Crossover, Ascending Dose-Tolerance Study To Assess The Safety And Pharmacokinetics Of Tafamidis Doses Greater Than 120 Mg As Oral Solution In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study in healthy male and female volunteers will investigate the safety and tolerability
      of three increasing oral doses of tafamidis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of orally administered tafamidis in healthy volunteers at escalating doses &gt;120 mg. Safety assessments will include spontaneous reporting of adverse events, concomitant medications, physical examination,</measure>
    <time_frame>Day 0 and Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>vital signs, ECGs, and clinical laboratory tests.</measure>
    <time_frame>Day 0 and Day 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax - Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax - Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 - AreArea under the Concentration-Time Curve (AUC)</measure>
    <time_frame>0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast - Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]</measure>
    <time_frame>0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf - Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</measure>
    <time_frame>0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ - Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transthyretin blood concentration in mg/dL</measure>
    <time_frame>Days 0,1,2,3,4,5,6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transthyretin stabilization (%)</measure>
    <time_frame>Days 0,1,2,3,4,5,6</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>TTR Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240 mg tafamidis arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>480 mg arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBD dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafamidis</intervention_name>
    <description>240 mg, solution, single dose</description>
    <arm_group_label>Period 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafamidis</intervention_name>
    <description>480 mg, solution, single dose</description>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafamidis</intervention_name>
    <description>TBD dose will be a single dose if &lt; 720 mg or a loading dose followed by additional dose if &gt; 720 mg.</description>
    <arm_group_label>Period 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, males or females, 21 to 55 years old.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.

        Exclusion Criteria:

        Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,
        gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
        (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the
        time of dosing).

        Condition affecting drug absorption. Blood pressure or ECG abnormalities. Recent treatment
        with an investigational, prescription, or non-prescription drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461040&amp;StudyName=Safety%20And%20Pharmacokinetic%20Assessment%20Of%20Orally%20Administered%20Tafamidis%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <last_update_submitted>September 26, 2012</last_update_submitted>
  <last_update_submitted_qc>September 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

